Adherence to varenicline in the COMPASS smoking cessation intervention trial

Nicotine and Tobacco Research

Volumn 13, Issue 5, 2011, Pages 361-368

  Catz, Sheryl L ^a   Jack, Lisa M ^b   McClure, Jennifer B ^a   Javitz, Harold S ^b   Deprey, Mona ^c   Zbikowski, Susan M ^c   McAfee, Tim ^d   Richards, Julie ^a   Swan, Gary E ^b  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b SRI INTERNATIONAL   (United States)

^c Free and Clear Inc   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE;

ADULT; ARTICLE; DEMOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; SELF REPORT; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

EID: 79956095931     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntr003     Document Type: Article

References (37)

1. Blondal, T., Franzon, M., & Westin, A. (1997). A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. European Respiratory Journal, 10, 1585. doi:10.1183/09031936.97.10071585.
2. Bush, P. J., & Iannotti, R. J. (1993). Alcohol, cigarette, and marijuana use among fourth-grade urban schoolchildren in 1988/89 and 1990/91. American Journal of Public Health, 83, 111-114.
3. Cahill, K., Stead, L. F., & Lancaster, T. (2008). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Review, (3). CD006103. doi:10.1002/14651858.CD006103.pub3.
4. Clifford, S., Barber, N., & Horne, R. (2008). Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: Application of the necessity-concerns framework. Journal of Psychosomatic Research, 64, 41-46. doi:S0022-3999(07)00206-1 [pii] 10.1016/j.jpsychores.2007.05.004.
5. Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974). The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behavioral Science, 19, 1-15.
6. DiMatteo, M. R., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002). Patient adherence and medical treatment outcomes: A meta-analysis. Medical Care, 40, 794-811. doi:10.1097/01.MLR.0000024612.61915.2D.
7. Fiore, M. C., Jaen, C. R., Baker, T. B., Bailey, W.C., Benowitz, N.L., Curry, S.J., et al. (2008). Treating tobacco use and dependence: 2008 update; Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service.
8. Fucito, L. M., Toll, B. A., Salovey, P., & O'Malley, S. S. (2009). Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment. Psychology of Addictive Behaviors, 23, 373-379. doi:2009-08896-022 [pii] 10.1037/a0015695.
9. Garvey, A. J., Kinnunen, T., Nordstrom, B. L., Utman, C. H., Doherty, K., Rosner, B., et al. (2000). Effects of nicotine gum dose by level of nicotine dependence. Nicotine & Tobacco Research, 2, 53-63.
10. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of American Medical Association, 296, 47-55. doi:296/1/47 [pii] 10.1001/jama.296.1.47.
11. Hajek, P., West, R., Foulds, J., Nilsson, F., Burrows, S., & Meadow, A. (1999). Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Archives of Internal Medicine, 159, 2033-2038.
12. Halperin, A. C., McAfee, T. A., Jack, L. M., Catz, S. L., McClure, J. B., Deprey, T. M., et al. (2009). Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. Journal of Substance Abuse Treatment, 36, 428-434. doi:S0740-5472(08)00149-9 [pii] 10.1016/j.jsat.2008.09.001.
13. Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008). Interventions for enhancing medication adherence. Cochrane Database of Systematic Review, (2). CD000011. doi:10.1002/14651858.CD000011.pub3.
14. Hays, J. T., Leischow, S. J., Lawrence, D., & Lee, T. C. (2010). Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherence. Nicotine & Tobacco Research, 12, 574-581. doi:ntq047 [pii] 10.1093/ntr/ntq047.
15. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerstrom, K. O. (1991). The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
16. Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine, 337, 1195-1202. doi:10.1056/NEJM199710233371703.
17. Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., et al. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of American Medical Association, 296, 56-63. doi:296/1/56 [pii] 10.1001/jama.296.1.56.
18. Killen, J. D., Robinson, T. N., Ammerman, S., Hayward, C., Rogers, J., Stone, C., et al. (2004). Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. Journal of Consulting and Clinical Psychology, 72, 729-735. doi:10.1037/0022-006X.72.4.729 2004-16970-019 [pii].
19. Lam, T. H., Abdullah, A. S., Chan, S. S., Hedley, A. J., & Hong Kong Council on Smoking & Health Smoking Cessation Health Centre Steering Group. (2005). Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: A preliminary investigation. Psychopharmacology, 177, 400-408. doi:10.1007/s00213-004-1971-y.
20. Leabman, M. K., & Giacomini, K. M. (2003). Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics, 13, 581-584. doi:10.1097/01.fpc.0000054111.14659.2b.
21. Lee, J. H., Jones, P. G., Bybee, K., & O'Keefe, J. H. (2008). A longer course of varenicline therapy improves smoking cessation rates. Preventive Cardiology, 11, 210-214. doi:PRC003 [pii] 10.1111/j.1751-7141.2008.00003.x.
22. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34, 1115-1121. doi:CID010623 [pii] 10.1086/339074.
23. McClure, J., Swan, G., Jack, L., Catz, S., Zbikowski, S., McAfee, T., et al. (2009). Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. Journal of General Internal Medicine, 24, 563-569. doi:10.1007/s11606-009-0926-8.
24. Mooney, M. E., Sayre, S. L., Hokanson, P. S., Stotts, A. L., & Schmitz, J. M. (2007). Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: A replication and extension study. Addictive Behaviors, 32, 875-880. doi:S0306-4603(06)00202-4 [pii] 10.1016/j.addbeh. 2006.06.022.
25. Morisky, D. E., Green, L. W., & Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24, 67-74.
26. Nides, M., Oncken, C., Gonzales, D., Rennard, S., Watsky, E. J., Anziano, R., et al. (2006). Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine, 166, 1561-1568. doi:166/15/1561 [pii] 10.1001/archinte.166.15.1561.
27. Oncken, C., Cooney, J., Feinn, R., Lando, H., & Kranzler, H. R. (2007). Transdermal nicotine for smoking cessation in postmenopausal women. Addictive Behaviors, 32, 296-309. doi:S0306-4603(06)00132-8 [pii] 10.1016/j.addbeh.2006.04.004.
28. Park, D., & Liu, L. (2007). Medical adherence and aging: Social and cognitive perspectives. Washington, DC: American Psychological Association.
29. Schmitz, J. M., Stotts, A. L., Mooney, M. E., Delaune, K. A., & Moeller, G. F. (2007). Bupropion and cognitive-behavioral therapy for smoking cessation in women. Nicotine & Tobacco Research, 9, 699-709. doi:779329487 [pii] 10.1080/14622200701365335.
30. Shiffman, S., Sweeney, C. T., Ferguson, S. G., Sembower, M. A., & Gitchell, J. G. (2008). Relationship between adherence to daily nicotine patch use and treatment efficacy: Secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clinical Therapeutics, 30, 1852-1858. doi:S0149-2918(08)00309-3 [pii] 10.1016/j.clinthera.2008.09.016.
31. Swan, G. E., Javitz, H. S., Jack, L. M., Curry, S. J., & McAfee, T. (2004). Heterogeneity in 12-month outcome among female and male smokers. Addiction, 99, 237-250. doi:10.1111/j.1360-0443.2003.00629.x.
32. Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. (2010). Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490. doi:S0749-3797(10)00112-1 [pii] 10.1016/j.amepre.2010.01.024.
33. Toll, B. A., McKee, S. A., Martin, D. J., Jatlow, P., & O'Malley, S. S. (2007). Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine & Tobacco Research, 9, 597-605. doi:777521519 [pii] 10.1080/14622200701239662.
34. Tonstad, S., Tonnesen, P., Hajek, P., Williams, K. E., Billing, C. B., Reeves, K. R., et al. (2006). Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. Journal of American Medical Association, 296, 64-71. doi:296/1/64 [pii] 10.1001/jama.296.1.64.
35. Williams, K. E., Reeves, K. R., Billing, C. B., Jr., Pennington, A. M., & Gong, J. (2007). A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion, 23, 793-801. doi:10.1185/030079907X182185.
36. World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: World Health Organization.
37. Wroe, A. L. (2002). Intentional and unintentional nonadherence: A study of decision making. Journal of Behavioral Medicine, 25, 355-372. doi:10.1023/A:1015866415552.